

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bayzed Health Group Inc
佰澤醫療集團

(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 2609)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by Bayzed Health Group Inc (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) on a voluntary basis. The purpose of this announcement is to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the latest business development of the Group.

On May 31, 2024, Taiyuan Peace Hospital (太原和平醫院) of the Company, as China Hospital Rehabilitation Medical Consortium Standing Director Unit (中國醫院康復醫學聯合體常務理事單位), jointly launched an initiative for “Five Prescriptions (五大處方) for Oncology Rehabilitation” with over 30 large-scale medical institutions in China, such as Peking University Third Hospital (北京大學第三醫院) and Xiyuan Hospital of China Academy of Traditional Chinese Medical Sciences (中國中醫科學院西苑醫院) at the inaugural meeting of China Hospital Rehabilitation Medical Consortium. After the meeting, Taiyuan Peace Hospital worked with Peking University Third Hospital to organize 29 experts, including the Group’s seven experts, in the fields of oncology, nutrition, psychology and rehabilitation working at the well-known Class III hospitals to draft the “Expert Consensus on Oncology Rehabilitation (腫瘤康復專家共識)”, forming the “Expert Consensus on Oncology Rehabilitation (2025) (《腫瘤康復專家共識(2025)》)” by using the Delphi method (德爾菲法). This expert consensus was certified by the International Practice Guidelines Registration Platform (國際實踐指南註冊平台) on March 20, 2025, received a notice of Manuscript Acceptance from Chinese Journal of Clinicians on May 26, 2025 and was published in the journal on June 23, 2025.

Oncology rehabilitation has been an important step for improving patient’s quality of life, reducing the side effects of treatment and promoting functional recovery. This consensus cleared the applicable population and objectives of oncology rehabilitation, and proposed systematic assessment criteria for oncology rehabilitation, as well as scientific and feasible “Five Prescriptions” rehabilitation strategy, based on the latest global research and clinical experience. The consensus emphasized that oncology rehabilitation should be conducted across prehabilitation before treatment, rehabilitation intervention during therapy and long-term recovery, and multidisciplinary teams (MDTs) should play a central role in oncology rehabilitation. The Chinese Journal of Clinicians, in which, the consensus was published, is supervised by the National Health Commission of the PRC (中國國家衛生健康委員會) and is one of the Chinese Medical Association journals sponsored by the Chinese Medical Association. This journal has also been indexed in the Catalogue of Key Magazine of China Technology (中國科技核心期刊目錄) and Guide to the Core Journal of China (北大核心期刊目錄), boasting one of China’s most influential medical scientific journals.

The Board believes that consistently implementing the “Five Prescriptions” strategy for oncology rehabilitation covering exercise, nutrition, drug, psychology and pain relief, is a critical component of the full-cycle oncology healthcare services of the Group. The publication of Expert Consensus on Oncology Rehabilitation jointly drafted by the Group and the other third parties’ experts in the Chinese Medical Association journals indicates that the oncology rehabilitation business of the Group is fully recognized by the corresponding industry, showing the core competitiveness of the Group that differentiate itself from other medical institutions, and demonstrating the Group’s confidence towards its own business outlook and prospects, which would eventually bring benefits to the Company and creating value for the Shareholders.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Mr. Zhao Yongkai
Chairman and Executive Director

Hong Kong, June 26, 2025

As at the date of this announcement, Directors and proposed directors of the Company include: (i) Mr. Zhao Yongkai, Ms. Xu Xu, Dr. Chen Haoyang, Mr. Lu Jizhong and Mr. Feng Yu as executive Directors; and (ii) Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei as independent non-executive Directors.